Arthur Lee, MD
Interventional Cardiology · Gainesville, FLNPI 1063447977
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,326,764 of the $1,769,510 with a category attached, or 75.0%. 60 manufacturers reported payments, led by Johnson & Johnson at 30.9% of the total. Reporting peaked in 2022 at $340,433 and has fallen 78.5% since, to $73,137 in 2025. Among interventional cardiology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,314 payments — averaging $764.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$548K
- Amgen$468K
- Boehringer Ingelheim$206K
- Lilly USA, LLC$124K
- Bard Peripheral Vascular, Inc.$113K
- Angiodynamics, Inc.$56K
- plus $254K from 54 others
Across 70 payments — averaging $2825.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Trireme Medical LLC$37K
- Inari Medical, Inc.$32K
- Cook Research Incorporated$28K
- Medalliance LLC$28K
- Catheter Precision, Inc. FKA Ra Medical Systems, Inc.$24K
- Cardiovascular Systems Inc.$18K
- plus $31K from 4 others
What the payments were for
- Consulting fees$162,9949%
- Speaking & faculty fees$1,326,76475%
- Travel & lodging$173,33310%
- Food & beverage$64,8624%
- Education$720%
- Other$41,4852%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$543,432
- Repatha$464,053
- JARDIANCE$314,687
- Auryon Laser System 100-120 Vac$48,085
- LIMFLOW SYSTEM$39,508
- Inpefa$38,254
- Zilver PTX$26,171
- PERCLOSE PROGLIDE$19,301
- ADVANCE$13,890
- FARXIGA$12,312
- Peripheral Orbital Atherectomy System$12,056
- Vascepa$11,533
- DABRA 101 Catheter$9,082
- Indigo$8,135
- Indigo System$6,443
- CT THROMBECTOMY SYSTEM KIT$5,632
- FLOWTRIEVER CATHETER, S$5,453
- Cook Medical Micropuncture$5,200
- VenaCure 1470 Pro$4,360
- Cook Medical IAA$4,000
How this compares
$1,769,510 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 293 | $243,183 |
| EliquisApixaban | 254 | $226,030 |
| EntrestoSacubitril/Valsartan | 185 | $182,996 |
| JardianceEmpagliflozin | 207 | $151,805 |
| Repatha SureclickEvolocumab | 112 | $94,660 |
| Repatha PushtronexEvolocumab | 70 | $59,921 |
| VascepaIcosapent Ethyl | 60 | $30,591 |
| BrilintaTicagrelor | 38 | $20,483 |
| Flecainide Acetate | 69 | $2,665 |
| Metoprolol Succinate | 239 | $2,590 |
| ClopidogrelClopidogrel Bisulfate | 251 | $2,229 |
| Rosuvastatin Calcium | 200 | $2,074 |
| Atorvastatin Calcium | 275 | $1,975 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 75 | $1,349 |
| Carvedilol | 121 | $982 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $547,586 | $243,183293 claims |
| PfizerEliquis | $356 | $226,030254 claims |
| NovartisEntresto | $562 | $182,996185 claims |
| Boehringer IngelheimJardiance | $205,942 | $151,805207 claims |
| AstraZenecaBrilinta | $12,536 | $20,48338 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Gainesville
- Matheen KhuddusGainesville$164K
- Christopher CaputoGainesville$67K
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.